GlassScriptPhysician profile
Ali A Khan
NPI 1528089158
$21,409.89
in general payments reported to CMS, 2019-2025
45 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,461 · 2020: $2,092 · 2021: $2,569 · 2022: $2,177 · 2023: $2,423 · 2024: $7,432 · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,707 · Consulting Fee: $3,325 · Travel and Lodging: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,706.75 |
| Consulting Fee | $3,325.00 |
| Travel and Lodging | $1,079.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,142.49 | 2019-2025 | Krystexxa, Evenity |
| Astrazeneca Pharmaceuticals LP | $2,475.33 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,992.76 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $767.91 | 2019-2025 | Jardiance, Tradjenta |
| Esperion Therapeutics, INC. | $728.02 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $689.03 | 2019-2023 | |
| Horizon Therapeutics Plc | $670.18 | 2019-2023 | Krystexxa |
| Pfizer INC. | $626.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $555.10 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $541.13 | 2019-2025 | Verquvo, Lagevrio, Belsomra |
| Janssen Pharmaceuticals, INC | $514.59 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $468.73 | 2023-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $462.32 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $403.99 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $391.51 | 2019-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $369.01 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $338.77 | 2019-2024 | Ajovy, Austedo, Austedo Xr |
| Allergan, INC. | $299.82 | 2019-2020 | |
| Daiichi Sankyo INC. | $289.45 | 2019-2022 | |
| Exact Sciences Corporation | $280.14 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $279.54 | 2019-2021 | |
| Abbott Laboratories | $242.71 | 2021-2023 | Aveir, Freestyle Libre 2 |
| Astellas Pharma US INC | $225.93 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $218.65 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $197.04 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $187.31 | 2024-2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $156.77 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $155.25 | 2019-2025 | Camzyos |
| Xeris Pharmaceuticals, INC. | $150.44 | 2022-2024 | Gvoke Hypopen |
| Dexcom, INC. | $112.77 | 2021-2024 | Dexcom G6 Transmitter |
| Melinta Therapeutics, LLC | $68.64 | 2019 | |
| Vifor Pharma, INC. | $53.96 | 2023 | Veltassa |
| Biohaven Pharmaceuticals, INC. | $44.85 | 2020-2021 | |
| Viatris Specialty LLC | $44.70 | 2025 | Yupelri |
| Insulet Corporation | $44.09 | 2024 | Omnipod |
| Avanir Pharmaceuticals, INC. | $37.43 | 2020-2021 | |
| Corcept Therapeutics | $29.96 | 2024 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.00 | 2022 | |
| Calliditas Therapeutics US INC. | $22.15 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.50 | 2023 | Nuedexta |
| Eisai INC. | $20.96 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.86 | 2022 | |
| Shield Therapeutics INC | $15.58 | 2023 | Accrufer |
| Hemosonics LLC | $14.45 | 2025 | Qunatra Qplus System, Quantra Qplus System |
| Supernus Pharmaceuticals, INC. | $14.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.